Virbac completes divestment of U.S. Rights to SENTINEL® brands to MSD Animal Health
Virbac, today announced the successful completion of its divestment of the U.S. rights to its parasiticides for dogs: SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® to MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK). The consideration received for the transaction amounted to approximately US $400 million, subject to customary closing adjustments, settled in cash.
Virbac to divest U.S. Rights to SENTINEL® brands to MSD Animal Health
Under the terms of this agreement, Virbac will divest a combination of titles and rights for the United States on trademarks, marketing authorizations, patents, know-how, and other assets, related to two parasiticides for dogs: SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM®. In relation with the transaction, Virbac will keep its commercial structure substantially unchanged, and will continue to manufacture SENTINEL® SPECTRUM® at its Bridgeton, Missouri site for the next ten years.
The Every Dog Project is now The Every Pet Project!
Thanks to the ongoing support of The Every Dog Project, Virbac is expanding the initiative to become The Every Pet Project. It will now include all pets, with the intention of making an even bigger impact.
Francois Fournier, CEO of Virbac North America, explained the thinking behind the expansion:
“The Every Pet Project will help us do more for the communities we serve and enable us to improve the quality of care for pets that need it the most.”
Through The Every Pet Project, Virbac’s goal is to help ensure that EVERY PET, EVERYWHERE enjoys a happy life and is able to receive the care and protection they deserve. By engaging with clinics, pet owners, and various organizations, Virbac is striving to raise awareness about the project, help as many charities as possible, and draw attention to the unmet medical needs facing pets today.
Virbac Announces Availability of EASOTIC® (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs
WESTLAKE, TX, APRIL 9, 2020 — Virbac Corporation has announced the availability of EASOTIC (hydrocortisone aceponate, miconazole nitrate, gentamicin sulfate) Otic Suspension for Dogs, a prescription treatment for canine otitis externa.
François Fournier named President & CEO of Virbac North America
Virbac announces François Fournier’s appointment as President & CEO of Virbac North America, effective January 7, 2019. His main mission is to lead and develop all North American Virbac activities, in line with the Virbac Group’s global strategy.